Skip to main content

Advertisement

Log in

Tamoxifen Paradoxically Decreases Paclitaxel Deposition into Cerebrospinal Fluid of Brain Tumor Patients

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Summary

Background: P-glycoprotein (Pgp) mediates, in part, resistance to natural product chemotherapy drugs which constitute over half of the available drugs for cancer treatment. Tamoxifen (TAM) enhances intracellular deposition of natural product chemotherapy in human cell lines by inhibition of Pgp. Pgp is highly expressed in the choroid plexus and is thought to be a key component of the blood–cerebrospinal fluid barrier (BCSFB). We conducted a prospective, randomized study to assess if Pgp inhibition by TAM alters deposition of paclitaxel in cerebrospinal fluid (CSF).

Methods: Ten patients with either primary or metastatic brain tumors were randomized to: paclitaxel alone (175 mg/m2/IV) or a course of TAM (160 mg/m2 PO BID on Days 1–5) followed by paclitaxel (175 mg/m2/IV on Day 5). CSF and plasma samples were obtained following paclitaxel infusion; paclitaxel and TAM concentrations were measured by high-performance liquid chromatography assays.

Results: Paclitaxel was detected in the CSF of six of the 10 patients. Peak CSF paclitaxel concentrations of the paclitaxel and paclitaxel–TAM groups ranged between 3.5–57.4 and 2.3–24.6 nM, respectively. Though there was a 2.4-fold higher mean CSF paclitaxel concentration and a 3.7-fold higher median peak CSF:plasma paclitaxel ratio for those who received paclitaxel alone as compared to combined paclitaxel–TAM, it was not statistically significant (P = 0.22). In one patient enrolled to both arms, higher CSF concentrations of paclitaxel and higher paclitaxel CSF: plasma ratios were observed when given paclitaxel alone.

Conclusions: The trend towards lower paclitaxel CSF concentrations when given with TAM is consistent with the published finding that Pgp’s localization in the endothelial cells of the choroid plexus works in an opposite direction and keeps drugs in the CSF. Thus, agents which inhibit Pgp, such as TAM, may increase efflux of Pgp substrates out of the BCSFB and may paradoxically lower CSF concentrations of natural product chemotherapy drugs. Conceptually, this finding implies that the Pgp in the BBB and BCSFB keeps natural toxins such as paclitaxel, from entering the brain (BBB) and, if they do enter the brain, keeps them in the CSF (BCSFB) where they may be less harmful than if they re-entered the brain. Thus, our work supports this novel idea and adds to the understanding of the functions of the BCSFB.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. C Cordon-Cardo JP O’Brien D Casals L Rittman-Grauer JL Biedler MR Melamed JR Bertino (1989) ArticleTitleMultidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood–brain barrier sites Proc Natl Acad Sci USA 86 695 Occurrence Handle2563168 Occurrence Handle1:CAS:528:DyaL1MXovVWnsw%3D%3D

    PubMed  CAS  Google Scholar 

  2. VV Rao JL Dahlheimer ME Bardgett AZ Snyder RA Finch AC Sartorelli D Piwnica-Worms (1999) ArticleTitleChoroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood–cerebrospinal-fluid drug-permeability barrier Proc Natl Acad Sci USA 96 3900 Occurrence Handle10097135 Occurrence Handle1:CAS:528:DyaK1MXjslChsLo%3D

    PubMed  CAS  Google Scholar 

  3. E Berman M Adams R Duigou-Osterndorf L Godfrey B Clarkson M Andreeff (1991) ArticleTitleEffect of tamoxifen on cell lines displaying the multidrug-resistant phenotype Blood 77 818 Occurrence Handle1993221 Occurrence Handle1:CAS:528:DyaK3MXhslOqtbo%3D

    PubMed  CAS  Google Scholar 

  4. RL Fine CW Sachs ME Albers A Safa US Rao G Scarborough J Burchette C Jordan DL Trump (1993) Tamoxifen inhibition of MDR: laboratory to clinical studies Miyazaki (Eds) The Mechanism and New Approach on Drug Resistance of Cancer Cells Elsevier Amsterdam 323–332

    Google Scholar 

  5. AR Safa S Roberts M Agresti RL Fine (1994) ArticleTitleTamoxifen aziridine, a novel affinity probe for P-glycoprotein in multidrug resistant cells Biochem Biophys Res Commun 202 606 Occurrence Handle7913604 Occurrence Handle10.1006/bbrc.1994.1971 Occurrence Handle1:CAS:528:DyaK2cXkvF2ht7Y%3D

    Article  PubMed  CAS  Google Scholar 

  6. US Rao RL Fine GA Scarborough (1994) ArticleTitleAntiestrogens and steroid hormones: substrates of the human P-glycoprotein Biochem Pharmacol 48 287 Occurrence Handle7914405 Occurrence Handle10.1016/0006-2952(94)90099-X Occurrence Handle1:CAS:528:DyaK2cXlt1Gmurw%3D

    Article  PubMed  CAS  Google Scholar 

  7. DL Trump DC Smith PG Ellis MP Rogers SC Schold EP Winer TJ Panella VC Jordan RL Fine (1992) ArticleTitleHigh-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine J Natl Cancer Inst 84 1811 Occurrence Handle1359155 Occurrence Handle1:STN:280:ByyD2MbkslA%3D

    PubMed  CAS  Google Scholar 

  8. MR Fetell SA Grossman JD Fisher B Erlanger E Rowinsky J Stockel (1997) ArticleTitlePreirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium J Clin Oncol 15 3121 Occurrence Handle9294475 Occurrence Handle1:CAS:528:DyaK2sXmt1Sqtrs%3D

    PubMed  CAS  Google Scholar 

  9. JC Vergniol R Bruno G Montay A Frydman (1992) ArticleTitleDetermination of taxotere in human plasma by a semi-automated high-performance liquid chromatographic method J Chromatogr 582 273 Occurrence Handle1362729 Occurrence Handle1:CAS:528:DyaK3sXhsFI%3D

    PubMed  CAS  Google Scholar 

  10. LK Webster NA Crinis KH Stokes JF Bishop (1991) ArticleTitleHigh-performance liquid chromatographic method for the determination of toremifene and its major human metabolites J Chromatogr 565 482 Occurrence Handle1831461 Occurrence Handle1:CAS:528:DyaK3MXksVWit7c%3D

    PubMed  CAS  Google Scholar 

  11. MJ Glantz H Choy CM Kearns PC Mills LU Wahlberg EG Zuhowski P Calabresi MJ Egorin (1995) ArticleTitlePaclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors J Natl Cancer Inst 87 1077 Occurrence Handle7616600 Occurrence Handle1:CAS:528:DyaK2MXnt12nur0%3D

    PubMed  CAS  Google Scholar 

  12. KP O’Boyle Y Wang EL Schwartz DL Regl A Einzig JP Dutcher PH Wiernik SB Horwitz (1997) ArticleTitleDevelopment of two radioimmunoassays to detect paclitaxel in sera and in cerebrospinal, ascitic, and pleural fluids Cancer 79 1022 Occurrence Handle9041166 Occurrence Handle1:CAS:528:DyaK2sXhvVehsrg%3D

    PubMed  CAS  Google Scholar 

  13. SH Tseng MS Bobola MS Berger JR Silber (1999) ArticleTitleCharacterization of paclitaxel (Taxol) sensitivity in human glioma- and medulloblastoma-derived cell lines Neuro-Oncology 1 101 Occurrence Handle11550305 Occurrence Handle1:STN:280:DC%2BD3MrgtFCkug%3D%3D

    PubMed  CAS  Google Scholar 

  14. J Ducharme K Fried G Shenouda B Leyland-Jones IW Wainer (1997) ArticleTitleTamoxifen metabolic patterns within a glioma patient population treated with high-dose tamoxifen Br J Clin Pharmacol 43 189 Occurrence Handle9131952 Occurrence Handle10.1046/j.1365-2125.1997.05029.x Occurrence Handle1:CAS:528:DyaK2sXhvFClu7g%3D

    Article  PubMed  CAS  Google Scholar 

  15. AL Cheng SE Chuang RL Fine KH Yeh CM Liao JD Lay DS Chen (1998) ArticleTitleInhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen Biochem Pharmacol 55 523 Occurrence Handle9514088 Occurrence Handle10.1016/S0006-2952(97)00594-7 Occurrence Handle1:CAS:528:DyaK1cXmsV2jsQ%3D%3D

    Article  PubMed  CAS  Google Scholar 

  16. AL Cheng KH Yeh RL Fine SE Chuang CH Yang LH Wang DS Chen (1998) ArticleTitleBiochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma Hepatogastroenterology 45 1955 Occurrence Handle9951847 Occurrence Handle1:STN:280:DyaK1M7jsFeiug%3D%3D

    PubMed  CAS  Google Scholar 

  17. EA Lien K Wester PE Lonning E Solheim PM Ueland (1991) ArticleTitleDistribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients Br J Cancer 63 641 Occurrence Handle2021551 Occurrence Handle1:STN:280:By6B3MvotlA%3D

    PubMed  CAS  Google Scholar 

  18. M Vulpen Particlevan HB Kal MJ Taphoorn SY El-Sharouni (2002) ArticleTitleChanges in blood–brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review) Oncol Rep 9 683 Occurrence Handle12066192

    PubMed  Google Scholar 

  19. SM Chang JG Kuhn J Rizzo HI Robins SC Schold SuffixJr. AM Spence MS Berger M Mehta IF Pollack C Rankin MD Prados (1998) ArticleTitlePhase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report J Clin Oncol 16 2188 Occurrence Handle9626220 Occurrence Handle1:CAS:528:DyaK1cXktV2isbY%3D

    PubMed  CAS  Google Scholar 

  20. BL Lum S Kaubisch AM Yahanda KM Adler L Jew MN Ehsan NA Brophy J Halsey MP Gosland BI Sikic (1992) ArticleTitleAlteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance J Clin Oncol 10 1635 Occurrence Handle1403041 Occurrence Handle1:STN:280:ByyD3MbktFM%3D

    PubMed  CAS  Google Scholar 

  21. R Advani HI Saba MS Tallman JM Rowe PH Wiernik J Ramek K Dugan B Lum J Villena E Davis E Paietta M Litchman BI Sikic PL Greenberg (1999) ArticleTitleTreatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar) Blood 93 787 Occurrence Handle9920827 Occurrence Handle1:CAS:528:DyaK1MXpsFyjsg%3D%3D

    PubMed  CAS  Google Scholar 

  22. EK Rowinsky L Smith YM Wang P Chaturvedi M Villalona E Campbell C Aylesworth SG Eckhardt L Hammond M Kraynak R. Drengler J Stephenson SuffixJr MW Harding DD VonHoff (1998) ArticleTitlePhase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP J Clin Oncol 16 2964 Occurrence Handle9738565 Occurrence Handle1:CAS:528:DyaK1cXmtFSls7g%3D

    PubMed  CAS  Google Scholar 

  23. WT Couldwell DR Hinton AA Surnock CM DeGiorgio LP Weiner ML Apuzzo L Masri RE Law MH Weiss (1996) ArticleTitleTreatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen Clin Cancer Res 2 619 Occurrence Handle9816211 Occurrence Handle1:CAS:528:DyaK28Xis1Wltb8%3D

    PubMed  CAS  Google Scholar 

  24. MC Chamberlain PA Kormanik (1995) ArticleTitleSalvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas Arch Neurol 56 703

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Robert L. Fine.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, J., Balmaceda, C., Bruce, J.N. et al. Tamoxifen Paradoxically Decreases Paclitaxel Deposition into Cerebrospinal Fluid of Brain Tumor Patients. J Neurooncol 76, 85–92 (2006). https://doi.org/10.1007/s11060-005-4171-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-005-4171-7

Keywords

Navigation